FY2030 revenue of ¥70 billion, ROE above 8%, and PBR above 1.0x

「Under its medium-term management policy, “FUSO Vision 2030 Next Stage,” the Company has set revenue of ¥70 billion and ROE above 8% as its management targets for fiscal 2030. In addition, the Company aims to achieve a PBR above 1x over the medium to long term by reducing its cost of capital through lower volatility resulting from more stable performance, stronger shareholder and investor relations, enhanced investor understanding through communication with investors, and the creation of social value through sustainability initiatives, while working to improve its PER by increasing expectations for the Company’s future through the development of breakthrough new drugs and other measures.」